NEW YORK – September 3, 2024
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024 in New York City.
The presentation will take place on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace in New York, NY. An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.
In addition, Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a panel titled “Non-Amyloid-Targeted Approaches in Treatment of Alzheimer’s Disease” taking place September 10, 2024 at 2:00 p.m. ET at the Lotte New York Palace in New York, NY.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
Good afternoon! I really liked the ease of use of the valor bet website. Registration took only a few minutes, and the interface is so intuitive that even a beginner can quickly figure out where everything is. As for the games, the choice is huge! There is everything from your favourite slots to popular table games such as roulette or blackjack. Another advantage is the opportunity to get generous bonuses that make the game even more exciting. I definitely recommend it!
When selecting an online casino platform, it's really important to pick one that is licensed and properly regulated to ensure fair gameplay and solid security. A trustworthy site should use encryption to safeguard your data and make privacy a priority. Additionally, checking for independent audits, like those from eCOGRA, can be a good way to confirm that the games are fair. From what I’ve seen, platforms like BC Game are often recommended due to their transparency and security features. You can even download bc game app, which regularly updates with new games, bonuses, and tournaments, though it doesn’t involve real-money betting. Always make sure to review the platform’s licensing and safety measures before signing up to get the best possible…
My friends and I are huge cricket fans, and we’re always looking for the latest news and analysis. I decided to search for a platform that could provide real-time updates and insider info. That’s when I discovered https://bestcricket.in/ . The site is super easy to navigate, and you can find everything you need about your favorite teams and matches. Plus, they offer some cool bonuses like prediction contests and free reports on upcoming games. I really enjoy the convenience of having all this cricket info in one place.
Hello! I recently had the good fortune to be introduced to https://nakedai.ai/ and I was pleasantly surprised. The site allows you to create fake nude photos with amazing accuracy. The quality of the images impressed me with its realism and it is really impressive. Naked AI is a great example of how technology can reach new heights in visual content creation. I recommend everyone to try this site!